References
- Braun M, Wassmer G, Klotz T, et al. Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’. Int J Impot Res 2000;12:305–11
- Amano T, Imao T, Takemae K, et al. Testosterone replacement therapy by testosterone ointment relieves lower urinary tract symptoms in late onset hypogonadism patients. Aging Male 2011;13:242–6
- Yokoyama O, Yoshida M, Kim SC, et al. Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia:a randomized placebo-and tamsulosin-controlled 12-week study in Asian men. Int J Urol 2013;20:193–201
- Shigehara K, Sugimoto K, Konaka H, et al. Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy:a randomized controlled study. Aging Male 2011;14:53–8
- Lepor H. Pathophysiology of lower urinary tract symptoms in the aging male population. Rev Urol 2005;7:S3–11
- Lunenfeld B, Nieschlag E. Testosterone therapy in the aging male. Aging Male 2007;10:139–53
- Lunenfeld B, Mskhalaya G, Zitzmann M, et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male 2015;18:5–15
- McVary K. Lower urinary tract symptoms and sexual dysfunction:Epidemiology and pathophysiology. BJU Int 2006;97(2 suppl):23–8
- Gacci M, Eardley I, Giuliano F, et al. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostate hyperplasia. Eur Urol 2011;60:809–25
- Morelli A, Filippi S, Comeglio P, et al. Acute vardenafil administration improves bladder oxygenation in spontaneously hypertensive rats. J Sex Med 2010;7:107–20
- Morelli A, Sarchielli E, Comeglio P, et al. Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. J Sex Med 2011;8:2746–60
- Lowe FC. Treatment of lower urinary tract symptoms suggestive of benign prostate hyperplasia:sexual function. BJU Int 2005;95:12–18
- Yan H, Zong H, Cui Y, et al. The efficacy of PDE5 inhibitors alone or in combination with alpha-blockers for the treatment of erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia:a systemic review and meta-analysis. J Sex Med 2014;11:1539–45
- Braun MH, Sommer F, Haupt G, et al. Lower urinary tract symptoms and erectile dysfunction:Co-morbidity or typical “Aging Male” symptoms? Results of the “Cologne Male Survey”. Eur Urol 2003;44:588–94
- Ponholzer A, Temml C, Obermayr R, Madersbacher S. Association between lower urinary tract symptoms and erectile dysfunction. Urology 2004;64:772–76
- Frankel SJ, Donovan JL, Peters TI, et al. Sexual dysfunction in men with lower urinary tract symptoms. J Clin Epidemiol 1998;51:677–85
- Aslan G, Cavus E, Karas H, et al. Association between lower urinary tract symptoms and erectile dysfunction. Arch Androl 2006;52:155–62
- Leliefeld HH, Stoevelaar HJ, McDonnell J. Sexual function before and after various treatments for symptomatic benign prostate hyperplasia. BJU Int 2002;89:208–13
- Ishizuka O, Matsuyama H, Sasaki H, et al; the KING study group. Nocturia potentially influences maintenance of sexual function in elderly men with benign prostate hyperplasia. LUTS 2013;5:75–81
- Irwin DE, Milsom I, Reilly K, et al. Overactive bladder is associated with erectile dysfunction and reduced sexual quality of life in men. J Sex Med 2008;5:2904–10
- Rogers R, Bachmann G, Jumadilova Z, et al. Efficacy of tolterodine on overactive bladder symptoms and sexual and emotional quality of life in sexually active women. Int Urogynecol J 2008;19:1551–7